Transgenic and knockout mice models to reveal the functions of tumor suppressor genes

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 235-257

  Taneja, Pankaj ^a   Zhu, Sinan ^a   Maglic, Dejan ^a   Fry, Elizabeth A ^a   Kendig, Robert D ^a   Inoue, Kazushi ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Ageing; BRCA; Ink4a Arf; Knockout mice; Mouse models; p53; Rb; Transgenic mice; Tumor suppressor genes

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER RESEARCH; CELL CYCLE; CELL PROLIFERATION; DEVELOPMENT; GENE FUNCTION; GENE MUTATION; HEREDITY; KNOCKOUT MOUSE; MOUSE; NEOPLASM; NONHUMAN; ONCOGENE; REVIEW; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

EID: 84860403811     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7516     Document Type: Review

References (187)

1. Kinzler KW, Vogelstein B. Cancer susceptibility genes. Gatekeepers and caretakers. Nature. 1997;386:761-763.
2. Sherr CJ. Principles of tumor suppression. Cell. 2004;116:235-246.
3. van Heemst D, den Reijer PM, Westendorp RG. Ageing or cancer: a review on the role of caretakers and gatekeepers. Eur J Cancer. 2007;43: 2144-2152.
4. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122:135-140.
5. Knudson AG. Chasing the cancer demon. Annu Rev Genet. 2000;34:1-19.
6. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer. 2007;7:645-658. Review.
7. Gopinathan A, Tuveson DA. The use of GEM models for experimental cancer therapeutics. Dis Model Mech. 2008;1:83-86.
8. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer. 2009;9:724-737.
9. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro. hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6:909-923.
10. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413-341.
11. Chan TA, Hwang PM, Hermeking H. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev. 2000;14:1584-1588.
12. Burns TF, Fei P, Scata KA. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol. 2003;23:5556-5571.
13. Donehower LA, Harvey M, Slagle BL, et al. Mice defcient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.
14. Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, et al. Enhanced pro-liferative potential in culture of cells from p53-defcient mice. Oncogene. 1993;8:3313-3322.
15. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4:1-7.
16. Purdie CA, Harrison DJ, Peter A, et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene. 1994;9:603-609.
17. Armstrong JF, Kaufman MH, Harrison DJ. High-frequency developmental abnormalities in p53-defcient mice. Curr. Biol. 1995;5:931-936.
18. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-defcient embryos exhibit exencephaly. Nat Genet. 1995;10: 175-180.
19. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-defcient mice by absence of p53. Nature. 1995;378: 206-208.
20. De MontesOcaLuna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-defcient mice by deletion of p53. Nature. 1995;378: 203-206.
21. Harvey M, McArthur MJ, Montgomery CA, Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen induced tumorigenesis in p53-defcient mice. Nat Genet. 1993;5:225-229.
22. Kemp CJ, Wheldon T, Balmain A. p53-defcient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet. 1994;8:66-69.
23. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet. 1993;66:83-92.
24. Kuperwasser C, Hurlbut GD, Kittrell FS, et al. 2000. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol. 2000;157:2151-2159.
25. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849-852.
26. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993,362:847-849.
27. Harvey M, Sands AT, Weiss RS, et al. In vitro growth characteristics of embryo fbroblasts isolated from p53-defcient mice. Oncogene. 1993;8: 2457-2467.
28. Cross SM, Sanchez CA, Morgan CA, et al. A p53-dependent mouse spindle checkpoint. Science. 1995;267:1353-1356.
29. Hollander MC, Sheikh MS, Bulavin DV, et al. Genomic instability in Gadd45 defcient mice. Nat Genet. 1999;23:176-184.
30. Blyth K, Terry A, O'Hara M, et al. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene. 1995;10: 1717-1723.
31. Harvey M, Vogel H, Lee E Y, Bradley A, Donehower LA. Mice defcient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res. 1995;55:1146-51.
32. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000;14:994-1004.
33. Godley LA, Kopp JB, Eckhaus M, Paglino JJ, Owens J, Varmus HE. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev. 1996;10:836-850.
34. Liu G, McDonnell TJ, de MontesOcaLuna R, et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000;97:4174-4179.
35. Chao C, Saito S, Kang J, et al. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. 2000;19:4967-4975.
36. Jimenez GS, Nister M, Stommel JM, et al. A transactivation-defcient mouse model provides insights into Trp53 regulation and function. Nat Genet. 2000;26:37-43.
37. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119:861-872.
38. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847-860.
39. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol. 1989;9: 3982-3991
40. Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002;415:45-53.
41. Ferbeyre G, Lowe SW. The price of tumour suppression? Nature. 2002;415: 26-27.
42. García-Cao I, García-Cao M, Martín-Caballero J, et al. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 2002;21:6225-6235.
43. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010;17:901-911.
44. Zawacka-Pankau J, Kostecka A, Sznarkowska A, Hedström E, Kawiak A. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle. 2010;9:720-728.
45. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008;68:2551-2556.
46. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000;407:645-648.
47. Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SF. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature. 2000;407:642-645.
48. Waltermann A, Kartasheva NN, Dobbelstein M. Differential regulation of p63 and p73 expression. Oncogene. 2003;22:5686-5693.
49. Stiewe T, Putzer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet. 2000;26:464-469.
50. Wu S, Murai S, Kataoka K, Miyagishi M. Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1. Biochem Biophys Res Commun. 2008;365:75-81.
51. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science. 2000;289:304-306.
52. Yang A, Walker N, Bronson R, et al. p73-defcient mice have neurological, pheromonal and infammatory defects but lack spontaneous tumours. Nature. 2000;404:99-103.
53. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708-713.
54. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714-718.
55. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416: 560-564.
56. Flores ER, Sengupta S, Miller JB, et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 2005;7:363-373.
57. Mastrangelo D, De Francesco S, Di Leonardo A, Lentini L, Hadjistilianou T. The retinoblastoma paradigm revisited. Med Sci Monit. 2008;14:RA231-RA240. Review.
58. Munakata T, Liang Y, Kim S, McGivern DR, Huibregtse J, et al. Hepatitis C virus induces E6AP dependent degradation of the retinoblastoma protein. PLoS Pathog. 2007;3:1335-1347.
59. Yokota J, Akiyama T, Fung YK, et al. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene. 1998;3: 471-475.
60. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;4:181-189.
61. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8:671-682. Review.
62. Cobrinik D, Lee MH, Hannon G, et al. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev. 1996;10:1633-1644.
63. Cobrinik D. Pocket proteins and cell cycle control. Oncogene. 2005;24: 2796-2809.
64. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25: 5220-5227. Review.
65. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000;60:3689-3695.
66. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol. 2007;8:703-713.
67. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 2009;9:785-797. Review.
68. Hallstrom TC, Nevins JR. Balancing the decision of cell proliferation and cell fate. Cell Cycle. 2009;8:532-535. Review.
69. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002;3:11-20. Review.
70. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature. 1992;359:295-300.
71. Almasan A, Yin Y, Kelly RE, et al. Defciency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F responsive genes, and apoptosis. Proc Natl Acad Sci U S A. 1995;92:5436-5440.
72. Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol. 2007;19:649-657. Review.
73. Vigo E, Muller H, Prosperini E, et al. CDC25A phosphatase is a target of E2F and is required for effcient E2F-induced S phase. Mol Cell Biol. 1999;19:6379-6395.
74. Moroni MC, Hickman ES, Denchi EL, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol. 2001;3:552-8.
75. Lazzerini Denchi E, Helin K. E2F1 is crucial for E2F-dependent apoptosis. EMBO Rep. 2005;6:661-668.
76. Clarke AR, Maandag ER, van Roon M, et al. Requirement for a functional Rb-1 gene in murine development. Nature. 1992;359:328-330.
77. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature. 1992;359:295-300.
78. Lee EY, Chang CY, Hu N, et al. Mice defcient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature.1992;359: 288-294.
79. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-defciency in the developing mouse lens. Nature. 1994;371:72-74.
80. Maandag EC, van der Valk M, Vlaar M, et al. Developmental rescue of an embryoniclethal mutation in the retinoblastoma gene in chimeric mice. EMBO J. 1994;13:4260-6428.
81. Williams BO, Schmitt EM, Remington L, et al. Extensive contribution of Rb-defcient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 1994;13:4251-4259.
82. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-defcient mouse embryos. Mol Cell. 1998;2:293-304.
83. Ziebold U, Reza T, Caron A, Lees JA. 2001. E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev. 15:386-391.
84. de Bruin A, Wu L, Saavedra HI, et al. Rb function in extraembryonic lineages suppresses apoptosis in the CNS of Rb-defcient mice. Proc Natl Acad Sci U S A. 2003;100:6546-6551.
85. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature. 2000;407:592-598.
86. Robanus-Maandag E, Dekker M, van der Valk M, et al. p107 is a suppressor of retinoblastoma development in pRb-defcient mice. Genes Dev. 1998;12: 1599-1609.
87. Dannenberg JH, van Rossum A, Schuijff L, te Riele H. Ablation of the retin-oblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev. 2000;14:3051-3064.
88. Sage J, Mulligan GJ, Attardi LD, et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 2000;14:3037-3050.
89. Berman SD, Calo E, Landman AS, et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A. 2008;105:11851-11856.
90. Choi J, Curtis SJ, Roy DM, Flesken-Nikitin A, Nikitin AY. Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb defciency. Am J Pathol. 2010;177:2645-2658.
91. Bignon YJ, Chen Y, Chang CY, Riley DJ, Windle JJ, et al. Expression of a retinoblastoma transgene results in dwarf mice. Genes Dev. 1993;7: 1654-1662.
92. Nikitin AYu, Shan B, Flesken-Nikitin A, Chang KH, Lee WH. The retino-blastoma gene regulates somatic growth during mouse development. Cancer Res. 2001;61:3110-3118.
93. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378:F115-F177.
94. Dominguez-Brauer C, Brauer PM, Chen YJ, Pimkina J, Raychaudhuri P. Tumor suppression by ARF: gatekeeper and caretaker. Cell Cycle. 2010;9: 86-89.
95. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2:731-737. Review.
96. Sherr CJ, Bertwistle D, DEN Besten W, et al. p53-Dependent and -independent functions of the Arf tumor suppressor. Cold Spring Harb Symp Quant Biol. 2005;70:129-137. Review.
97. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specifc inhibition of cyclin D/CDK4. Nature. 1993;366:704-707.
98. Liao MJ, Van Dyke T. Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma. Genes Dev. 1999;13:1246-1250.
99. Tam SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res. 1994;54:5816-5820.
100. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi- 1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164-168.
101. Ohtani N, Zebedee Z, Huot TJ, et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature. 2001;409:1067-1070.
102. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92:713-723.
103. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92:725-734.
104. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A. 1998;95:8292-8297.
105. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001-5014.
106. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006;6:663-673.
107. Dominguez-Brauer C, Brauer PM, Chen YJ, Pimkina J, Raychaudhuri P. Tumor suppression by ARF: gatekeeper and caretaker. Cell Cycle. 2010;9: 86-89. Review.
108. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol. 1998;18:6457-6473.
109. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12:2424-2433.
110. de Stanchina E, McCurrach ME, Zindy F, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 1998;12:2434-2442.
111. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c- Myc-in-duced apoptosis via INK4a/ARF. Genes Dev. 1999;13:2678-2690.
112. Jacobs JJ, Keblusek P, Robanus-Maandag E, et al. Senescence bypass screen identifes TBX2 which represses Cdkn2a (p19(ARF)) and is ampli-fed in a subset of human breast cancers. Nat Genet. 2000;26: 291-299.
113. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999;13: 2207-2217.
114. Maeda T, Hobbs RM, Merghoub T, Guernah I, Zelent A, et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature. 2005;433:278-285.
115. Linggi B, Müller-Tidow C, van de Locht L, et al. The t(8;21) fusion protein, AML1 ETO, specifcally represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med. 2002; 8:743-750.
116. Inoue K, Roussel MF, Sherr CJ. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A. 1999;96:3993-3998.
117. Inoue K, Mallakin A, Frazier DP. Dmp1 and tumor suppression. Oncogene. 2007;26:4329-4335.
118. Bates S, Phillips AC, Clark PA, Stott F, Peters G, et al. p14 ARF links the tumour suppressors RB and p53. Nature. 1998;395:124-125.
119. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85:27-37.
120. Orlow I, Rabbani F, Chin L, et al. Involvement of the Ink4a gene (p16 and p19arf) in murine tumorigenesis. Int J Oncol. 1999;15:17-24.
121. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 1997;11:2822-2834.
122. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91:649-659.
123. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-defcient mice. Cancer Res. 1999;59:2217-2222.
124. Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA. The differential impact of p16(INK4a) or p19(ARF) defciency on cell growth and tumorigenesis. Oncogene. 2004;23:379-385.
125. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature. 2001;413:86-91.
126. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature. 2001;413:83-86.
127. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, et al. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A. 2003;100:15930-15935.
128. Randle DH, Zindy F, Sherr CJ, Roussel MF. Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc Natl Acad Sci U S A. 2001;98: 9654-9659.
129. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2006;103:6688-6693.
130. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004;22:247-306. Review.
131. Drucker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
132. Williams RT, den Besten W, Sherr CJ. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 2007;21:2283-2287.
133. Yang C, Ionescu-Tiba V, Burns K, et al. The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer. Am J Pathol. 2004; 164:1031-1038.
134. Matheu A, Pantoja C, Efeyan A, et al. Increased gene dosage of Ink4a/ Arf results in cancer resistance and normal aging. Genes Dev. 2004;18: 2736-2746.
135. Matheu A, Maraver A, Klatt P, et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature. 2007;448:375-379.
136. Matheu A, Maraver A, Collado M, et al. Anti-aging activity of the Ink4/Arf locus. Aging Cell. 2009;8:152-161.
137. Krishnamurthy J, Torrice C, Ramsey MR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114:1299-1307.
138. Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature. 2006;443:453-457.
139. Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998;12:2899-2911.
140. Latres E, Malumbres M, Sotillo R, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 2000;19:3496-3506.
141. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27 Kip1 is haplo-insuffcient for tumour suppression. Nature. 1998;396: 177-180.
142. Zindy F, Cunningham JJ, Sherr CJ, Jogal S, Smeyne RJ, Roussel MF. Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases. Proc Natl Acad Sci U S A. 1999;96:13462-13467.
143. Uziel T, Zindy F, Xie S, et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev. 2005;19:2656-2667.
144. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet. 1998;32:95-121.
145. Deng CX, Xu X. Generation and analysis of Brca1 conditional knockout mice. Methods Mol Biol. 2004;280:185-200.
146. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408:429-432.
147. Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bio Essays. 2000;22:728-737.
148. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1 defciency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet. 1996;12:191-194.
149. Hakem R, de la Pompa JL, Sirard C, et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell. 1996;85:1009-1023.
150. Liu CY, Flesken-Nikitin A, Li S, Zeng Y, Lee WH. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 1996;10:1835-1843.
151. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nul-lizygous embryos. Genes Dev. 1997;11:1226-1241.
152. Evers B, Jonkers J. Mouse models of BRCA1 and BRCA2 defciency: past lessons, current understanding and future prospects. Oncogene. 2006;25: 5885-5897.
153. Hakem R, de la Pompa JL, Mak TW. Developmental studies of Brca1 and Brca2 knock-out mice. J Mammary Gland Biol Neoplasia. 1998;3: 431-445.
154. Deng CX, Brodie SG. Knockout mouse models and mammary tumorigenesis. Semin Cancer Biol. 2001;11:387-394. Review.
155. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science. 1998;281:1009-1012.
156. Shen SX, Weaver Z, Xu X, Li C, Weinstein M, et al. A targeted disruption of the murine Brca1 gene causes gamma irradiation hypersensitivity and genetic instability. Oncogene. 1998;17:3115-3124.
157. Chandler J, Hohenstein P, Swing D, et al. Human BRCA1 gene rescues the embryonic lethality of Brca1 mutant mice. Genesis. 2001;29:72-77.
158. Lane TF, Lin C, Brown MA, Solomon E, Leder P. Gene replacement with the human BRCA1 locus: tissue specifc expression and rescue of embryonic lethality in mice. Oncogene. 2000;19:4085-4090.
159. Mak TW, Hakem A, McPherson JP, et al. Brca1 is required for T cell lineage development but not TCR loci rearrangement. Nat Immunol. 2000;1:77-82.
160. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet. 1999;22:37-43.
161. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007;104: 12111-12116.
162. Brodie SG, Xu X, Qiao W. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene. 2001;20:7514-7523.
163. Hoshino A, Yee CJ, Campbell M, et al. Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia. Int J Biol Sci. 2007;3:281-291.
164. Chen J, Silver DP, Walpita D, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell. 1998;2:317-328.
165. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997;386:804-810.
166. Suzuki A, de la Pompa JL, Hakem R, et al. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. 1997;11:1242-1252.
167. Connor F, Bertwistle D, Mee PJ, et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet. 1997;17:423-430.
168. Friedman LS, Thistlethwaite FC, Patel KJ, et al. Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 1998;58:1338-1343.
169. Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell. 1998;1:347
170. Tutt A, Gabriel A, Bertwistle D, et al. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplifcation. Curr Biol. 1999;9:1107-1110.
171. Yu VP, Koehler M, Steinlein C, et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev. 2000;14:1400-1406.
172. Ludwig T, Fisher P, Murty V, Efstratiadis A. Development of mammary adenocarcinomas by tissue-specifc knockout of Brca2 in mice. Oncogene. 2001;20:3937-3948.
173. Cheung AM, Elia A, Tsao MS, et al. Brca2 defciency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice. Cancer Res. 2004;64:1959-1965.
174. Cheung AM, Hande MP, Jalali F, et al. Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. Cancer Res. 2002;62:6194-6204.
175. Park PG, Lee H. Development of thymic lymphomas in mice disrupted of Brca2 allele in the thymus. Exp Mol Med. 2008;40:339-344.
176. Lee H, Trainer AH, Friedman LS et al. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell. 1999;4:1-10.
177. Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A. Brca2 and Trp53 defciency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet. 2010;6:e1000995.
178. Yu Y, Xu F, Peng H, et al. NOEY2 (ARH1), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A. 1999;96:214-219.
179. Xu F, Xia W, Luo RZ, et al. The human ARH1 tumor suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res. 2000;60:4913-4920.
180. Lu Z, Luo RZ, Lu Y, et al. The tumor suppressor gene ARH1 regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008;118:3917-3929.
181. Sexl V, Diehl JA, Sherr CJ, Ashmun R, Beach D, Roussel MF. A rate limiting function of cdc25 A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene. 1999;18:573-582.
182. Cole MD, Nikiforov MA. Transcriptional activation by the Myc oncoprotein. Curr Top Microbiol Immunol. 2006;33-50. Review.
183. Lebofsky R, Walter JC. New Myc-anisms for DNA replication and tumorigenesis? Cancer Cell. 2007;12:102-103.
184. Sugiyama T, Frazier DP, Taneja P, et al. Signal transduction involving the Dmp1 transcription factor and its alteration in human cancer. Clinical Medicine Oncology. 2008;2:209-219.
185. Inoue K, Sugiyama T, Taneja P, Morgan RL, Frazier DP. Emerging roles of DMP1 in lung cancer. Cancer Res. 2008;68:4487-4490.
186. Sugiyama T, Frazier DP, Taneja P, Morgan RL, Willingham MC, Inoue K. The role of Dmp1 and its future in lung cancer diagnostics. Expert Rev Mol Diagn. 2008;8:435-448.
187. Taneja P, Maglic D, Kai F, et al. Critical role of Dmp1 in HER2/ neu-p53 signaling and breast carcinogenesis. Cancer Res. 2010;70:2084-2094.